AEON Biopharma To Participate In Lake Street Capital Markets' 10Th Annual Best Ideas Growth (BIG10) Conference

(MENAFN- GlobeNewsWire - Nasdaq) ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the“Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX^® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10^th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10^th, 2026.

To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX^®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau^®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit .

Contacts

Investor Contact:
Hershel Berry
Blueprint Life Science Group
...

Source: AEON

MENAFN31082026004107003653ID1111600887